CareDx Investor Relations Material

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers UNITY HEART, a precision medicine platform to diagnose the degree of cardiac allograft rejection without the need for a confirmatory endomyocardial biopsy; and UNITY OV, an automated whole blood donor screening system to detect donor-derived cell-free DNA prior to solid organ transplantation and non-invasive as well as categorical monitoring of allograft injury. The company also provides AlloMap heart transplant test that measure mRNA transcripts from 22 genes expressed in immune cells and fibroblasts for personalized patient management; and AlloSure kidney transplant test to measure the amount of a donor specific DNA in a recipient’s bloodstream.